A decade on from the very first US biosimilar approval, and 15 years on from the Biologics Price Competition and Innovation Act framework that provided the framework for the US Food and Drug Administration biosimilars pathway, Craig Burton – executive director of the Biosimilars Council within the US Association for Accessible Medicines – is clear on the progress made for biosimilars so far.
After A Decade Of US Biosimilars, ‘The Challenges Are Becoming More Clear’
Biosimilars Council Chief Craig Burton Discusses Progress And The Road Ahead
As the US marks 10 years since the first biosimilar approval and launch, AAM Biosimilars Council executive director Craig Burton talks to Generics Bulletin about the lessons learned so far and the path ahead, including how to move on from market models that have proved to be “not appropriate” for biosimilars.
